OCUL - A quarter of big progress should start to garner interest

8 ส.ค. 2019

OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would seem that the expectations at this point far underestimate the likely potential long-term adoption of DEXTENZA with expanded label and reimbursement codes in place. There is no doubt that DEXTENZA represents a step function improvement in an archaic and highly complex manual eye-drop regime, it should only be a matter of execution on the company's part to fully penetrate what should be a very sizable opportunity ($500 Million - $1 Billion plus) in post surgical inflammation and pain. As the market warms up to this reality, current valuation should expand significantly.